When was BioMerieux founded?

BioMerieux was founded in 1963 and raised its 1st funding round 46 years after it was founded.

Where is BioMerieux located?

BioMerieux is headquartered in Marcy l Étoile, France. It is registered at Durham, North Carolina.

Which legal entities is BioMerieux associated with?

BioMerieux is associated with BIOMERIEUX INDIA PRIVATE LIMITED and 3 others.

How many employees does BioMerieux have?

As of Sep 30, 2026, the latest employee count at BioMerieux is 12686.

Is BioMerieux a funded company?

BioMerieux is a funded company, having raised an undisclosed amount across 12 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on 2009.

When was the latest funding round of BioMerieux?

BioMerieux's latest funding was a $***** Grant (prize money) round on Nov 01, 2023, with participation from 1 investor.

What is the annual revenue of BioMerieux?

Annual revenue of BioMerieux is more than ₹1,000 Cr as on Mar 31, 2025

Where does BioMerieux rank among its competitors?

BioMerieux ranks 22nd amongst 2775 active competitors, of which 102 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Biorad Medisys, which secured $47.9M in May, 2024.

Who are the top competitors of BioMerieux?

BioMerieux's top competitors include Medtronic, Boston Scientific and Abbott. Among them, Biorad Medisys secured the most recent funding round in May, 2024.

BioMerieux - 2026 Company Profile, Funding, Competitors & Financials

Company Details

BioMerieux is a developer of diagnostics devices for multiple health purposes. It engages in the design, development, manufacture, and marketing of diagnosis systems. The company specializes in three main areas such as in-vitro diagnostics, clinical diagnostics, and industrial microbiological control. The company's in-vitro diagnostics clinical applications include the diagnosis of infectious diseases, such as hepatitis, HIV, tuberculosis, and respiratory infections, as well as pathologies, such as cardiovascular diseases and cancers. Its industrial applications include analysis of industrial samples, including food, pharmaceutical, and cosmetic products, or an environmental sample, such as water, air, and surface to determine its microbiological quality. In 2020, the company recorded annual revenues of $3.6 B and a net profit of $461 M.

Website: www.biomerieux.com/us/en.html
Social
Phone Number: +33 **********
Registered Address: Durham, North Carolina

Key Metrics

Founded Year

1963

Location

Marcy l Étoile, France

Stage

Public

Latest Funding Round

Grant (prize money), Nov 01, 2023, $*****

Investors

Digital Pharma Lab & 3 more

Ranked

22^nd among 2775 active competitors

Annual Revenue

₹1,000+ Cr as on Mar 31, 2025

Employee Count

12,686 as on Sep 30, 2026

Investment & Acquisitions

Plair & 26 more

Similar Companies

Medtronic & 2792 more

Exit Details

Public

View BioMerieux's full profile

BioMerieux is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Tongio Corp Se CIN: 21356556 , Czech Republic, Active	Mar 12, 2024	-	-
BIOMERIEUX NORGE AS CIN: 981062310 , Norway, Active	Aug 30, 1999	-	-
BIOMERIEUX INDIA PRIVATE LIMITED CIN: U85195DL1998PTC094403 , India, Active	Jun 10, 1998	₹1,000+ Cr (As on Mar 31, 2025)	355 (As on Mar 01, 2026)
Biomerieux, Inc. CIN: 431109770 , United States, Active	Dec 26, 999	-	6473 (As on Dec 31, 2024)	-

BioMerieux got listed on Jun 07, 2004.

Click here to take a look at BioMerieux's IPO in detail

BioMerieux has raised funding over 12 rounds. Its first funding round was on 2009. Its latest funding round was a Grant (prize money) round on Nov 01, 2023 for $*****. 1 investor participated in its latest round. BioMerieux has 4 institutional investors.

Here is the list of recent funding rounds of BioMerieux:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 01, 2023	3510509	Grant (prize money)	5039950	4671916	9405947	4539868
May 01, 2021	2582904	Grant (prize money)	3838953	9036814	1048566	Europa
Jan 01, 2020	1301075	Grant (prize money)	3209891	1555412	9636760	Europa

Access funding benchmarks and valuations. Sign up today!

View details of BioMerieux's funding rounds and investors

BioMerieux's employee count trend

BioMerieux has 12,686 employees as of Sep 26. Here is BioMerieux's employee count trend over the years:

Uncover BioMerieux's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BioMerieux include Medtronic, Boston Scientific and Abbott. Here is the list of Top 10 competitors of BioMerieux, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Medtronic 1949, Minneapolis (United States), Public	Manufacturer of medical technology and healthcare solutions	-	Greyrock Investments, Digital Pharma Lab ... & 26 others	83/100
2nd	Boston Scientific 1979, Marlborough (United States), Public	Wide range of medical devices	-	JANA Partners, Endeavour Vision & 12 others	82/100
3rd	Abbott 1888, Libertyville (United States), Public	Developer of medical devices, generic pharmaceuticals, and nutrition products	-	MSN Laboratories, Digital Pharma Lab & 12 others	73/100
4th	BD 1897, Franklin Lakes (United States), Public	Manufacturer and distributor of medical devices, diagnostic instruments, and laboratory equipment	-	Gershon Capital, Tekla Capital Management ... & 6 others	73/100
5th	Danaher 1969, Washington, DC (United States), Public	R&D company focused on manufacturing dental equipment for multiple therapeutic areas	-	Ventana Capital Management, Bank of America	71/100
6th	Trivitron 1997, Chennai (India), Series C	Provider of medical technology and devices for healthcare industry needs	$109M	Fidelity Investments, True North & 21 others	69/100
7th	HOYA 1941, Shinjuku (Japan), Public	Developer of a wide range of medical devices	-	-	66/100
8th	CONMED 1987, Utica (United States), Public	R&D company focused on manufacturing of surgical instruments for multiple therapeutic areas	-	Hudson River Capital Partners, J P Morgan Wealth Management ... & 2 others	66/100
9th	Biorad Medisys 2007, Pune (India), Series A	Manufacturer of medical devices for orthopaedic, neurovascular, and endovascular procedures	$53.4M	InvAscent, BioMediCon & 5 others	65/100
10th	Teleflex Medical 1943, Wayne (United States), Public	Provider of medical devices for emergency medicine and various health conditions	-	Amzak Health, TATRC & 2 others	64/100
22nd	BioMerieux 1963, Marcy l Étoile (France), Public	Developer of diagnostics devices for multiple health purposes	-	Digital Pharma Lab, Sofina & 2 others	58/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on BioMerieux's competitors? Click here to see the top ones

BIOMERIEUX INDIA PRIVATE LIMITED, the legal entity associated with BioMerieux, generated more than ₹1,000 Cr in revenue for the financial year ending on Mar 31, 2025. The revenue of BIOMERIEUX INDIA PRIVATE LIMITED has a compounded annual growth rate (CAGR) of 16% in the last 1 year.

Financial Statement Summary

Metrics	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21
Income Statement
Revenue	4859	3127	5845	1653	5521
Total Sales	5504	8386	3072	7678	9472
Total Expenses	7565	8035	6039	8647	9906
Operating Expenses	8539	6975	8011	8789	5290
Employee Expenses	1594	6201	9117	5239	1509
Marketing Expenses	5876	4596	7595	9513	7799
Operating Income (EBIT)	3196	3670	4394	1178	9019
Interest Expenses	2665	2849	3448	7744	1003
Expenses from other activities	1826	5442	2489	7731	4535
EBITDA	4137	8850	1061	7563	6307
Taxes	9414	8558	3019	9362	8540
Net Profit	6609	1236	9072	3911	2426
Balance Sheet
Assets	5552	5050	4736	2429	5205
Cash Equivalent	1735	8855	4909	8474	2329
Accounts Receivables	7231	1177	7828	2485	8496
Inventory	5674	5677	6952	6508	5051
Liabilities	8886	3335	5013	8549	3414
Total Debt	4040	6804	1956	9173	4457
Accounts Payable	3413	2898	8619	7143	8281
Equities	9494	5668	1417	5528	5796
Cashflow Statement
Cash from Operating activities	5428	2380	9085	5746	5818
Cash from Investing activities	7585	7989	5528	2944	4971
Net cash from Financing activities	1993	8869	4301	8817	8893

Detailed Financials (Income Statement, Balance Sheet, Cashflow Statement)

BioMerieux has made 12 investments in companies including Plair and Nanopore Technologies. BioMerieux has also acquired 15 companies including Accellix and SpinChip.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Mar 27, 2026	Investments	Plair	2014	Plan les Ouates (Switzerland)
Jan 22, 2026	Acquisition	Accellix	2007	San Jose (United States)
Jan 13, 2025	Acquisition	SpinChip	2012	Oslo (Norway)